此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Prospective, Multicenter, Controlled Clinical Study of Collagen Fibrous Scaffold for the Treatment of Cesarean Scar Diverticulum (CSD-SCAFFOLD)

Cesarean scar diverticulum (CSD, uterine niche) is a common long-term complication of cesarean delivery, frequently presenting with abnormal vaginal bleeding (postmenstrual spotting, prolonged menses), pelvic pain, and adverse reproductive outcomes. Current surgical repair yields variable niche shrinkage and inconsistent symptom and fertility improvement. This prospective, multicenter, controlled study aims to evaluate the efficacy and safety of collagen fibrous scaffold implantation versus conventional repair alone. Eligible symptomatic women will be enrolled from multiple tertiary obstetrics and gynecology centers. The primary outcome is change in CSD niche volume measured by transvaginal three-dimensional ultrasound. Secondary outcomes include improvement of abnormal vaginal bleeding and reproductive outcomes. Participants will be followed at 1, 3, 6, and 12 months postoperatively.

研究概览

详细说明

This is a prospective, multicenter, parallel controlled interventional study in symptomatic women with cesarean scar diverticulum. Subjects meeting the inclusion criteria will be allocated to the intervention group (collagen fibrous scaffold implantation) or the control group (standard surgical repair without scaffold).

Baseline assessments include transvaginal 3D ultrasound for niche volume measurement, menstrual symptom diary, pelvic pain evaluation, reproductive history, pelvic imaging, and routine laboratory tests. The index repair surgery (hysteroscopic combined laparoscopic) is performed per standardized protocol by experienced gynecologic surgeons. In the intervention group, the collagen fibrous scaffold is placed at the CSD to support tissue regeneration and scar remodeling. The control group receives identical surgical repair without scaffold implantation.

Follow-up visits are scheduled at 1, 3, 6, and 12 months after surgery. At each visit, adverse events, vaginal bleeding pattern, menstrual duration, and pelvic discomfort are recorded. Transvaginal 3D ultrasound is performed to quantify niche volume. Reproductive data including spontaneous conception, clinical pregnancy, pregnancy continuation, and pregnancy complications are collected up to 12 months. Safety endpoints include intraoperative hemorrhage, visceral injury, surgical site infection, scaffold-related reactions, pelvic adhesion, and persistent pain. All adverse events are graded for severity and assessed for relatedness to the study device or procedure.

Primary analysis compares between-group difference in niche volume change from baseline to 6 months. Secondary analyses compare abnormal vaginal bleeding parameters and reproductive outcomes. Safety profiles will be summarized. Analyses will be conducted on intention-to-treat and per-protocol populations.

研究类型

介入性

注册 (估计的)

80

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Zhejiang Provincial Clinical Research Center for Gynecological Women's Hospital, Zhejiang University School of Medicine

学习地点

    • Zhejiang
      • Hangzhou、Zhejiang、中国、310006
        • Women's Hospital, School of Medicine, Zhejiang University
        • 接触:
        • 首席研究员:
          • Ning Wang, M.D

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  • At least one prior cesarean delivery
  • CSD confirmed by transvaginal 3D ultrasound with measurable niche volume
  • Symptomatic CSD: abnormal vaginal bleeding (prolonged menstruation, postmenstrual spotting, intermenstrual bleeding) attributed to the niche
  • Candidate for surgical CSD repair and willing to complete scheduled follow-up
  • Signed written informed consent

Exclusion Criteria:

  • Current pregnancy or unwillingness to use effective contraception for the first 6 months postoperatively
  • Coexisting uterine lesions requiring separate surgical intervention (submucous fibroids, large endometrial polyps, adenomyosis with dominant lesion)
  • Active pelvic inflammatory disease or untreated genital tract infection
  • Known allergy or hypersensitivity to collagen-derived biomaterials
  • Severe systemic disease or coagulopathy that contraindicates pelvic surgery
  • Suspected or confirmed gynecologic malignancy
  • Inability or unwillingness to complete required follow-up assessments

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm 1: Intervention Group

Collagen fibrous scaffold is implanted at the site of the cesarean scar diverticulum under 3D ultrasound guidance, without hysteroscopic or laparoscopic surgery.

The diverticulum is localized under hysteroscopic guidance, and diverticulectomy and scar repair are performed laparoscopically without implantable collagen fibrous scaffold .

其他名称:
  • Scaffold
有源比较器:Arm 2: Control Group

Identical hysteroscopic combined laparoscopic surgical repair of the CSD defect; no collagen fibrous scaffold is implanted.

The diverticulum is localized under hysteroscopic guidance, and diverticulectomy and scar repair are performed laparoscopically without placement of implantable collagen fibrous scaffold.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in cesarean scar niche volume (mL)
大体时间:Baseline, 3 months

Cesarean scar niche volume will be assessed by three-dimensional transvaginal ultrasound and calculated by the ellipsoid formula (V = 0.523 × length × width × depth)at baseline and 3 months after intervention.

Baseline, 3 months

次要结果测量

结果测量
措施说明
大体时间
Change from baseline in abnormal vaginal bleeding
大体时间:Baseline, 3, 6, 12 months

Assessed by menstrual diary, including total menstrual bleeding days, days of postmenstrual spotting, and intermenstrual bleeding episodes per menstrual cycle.

Baseline, 3, 6, 12 months
Reproductive outcome-clinical pregnancy rate
大体时间:Baseline to 12 months

Include clinical pregnancy rate among participants attempting conception.

Baseline to 12 months
Reproductive outcome- ongoing pregnancy rate
大体时间:Baseline to 12 months

Include ongoing pregnancy rate among participants attempting conception.

Baseline to 12 months
Reproductive outcome - early pregnancy loss rate
大体时间:Baseline to 12 months

Include early pregnancy loss rate among participants attempting conception.

Baseline to 12 months
Reproductive outcome - cesarean scar pregnancy rate
大体时间:Baseline to 12 months

Include cesarean scar pregnancy rate among participants attempting conception.

Baseline to 12 months
Incidence of adverse events
大体时间:Intraoperative through 12 months

All device-related and procedure-related adverse events, graded by severity and causality.

Intraoperative through 12 months
Recurrence rate of cesarean scar diverticulum
大体时间:12 months

Recurrence defined as reappearance of measurable niche on 3D ultrasound after initial shrinkage or resolution.

12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月6日

初级完成 (估计的)

2029年11月30日

研究完成 (估计的)

2032年11月6日

研究注册日期

首次提交

2026年11月5日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月12日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • WHZ-JXX
  • 2025C02122 (其他赠款/资助编号:the Zhejiang Province's 2025 'Pioneer Leading Swan + X' Science and Technology Program)
  • 2024ZY01028 (其他赠款/资助编号:the Zhejiang Provincial Central Leading Local Science and Technology Development Fund Project)
  • ZDFY2023-4XPY101 (其他赠款/资助编号:the 4+X Clinical Research of Women's Hospital, School of Medicine, Zhejiang University)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅